Single-chain HA with no cross-linkingHA Attributes
The primary endpoint in the 12-week pivotal trial
noninferiority by mean change from
baseline in VAS (100-mm scale)
score for the
average of 5 Western Ontario and McMaster
Osteoarthritis (WOMAC) Index pain
scores. Reduction from baseline
after the third injection: EUFLEXXA 62%
Synvisc 55% (P<0.0001).
The most commonly reported adverse events
in this trial were arthralgia (14/160), back pain
(8/160), and joint effusion (1/160).5
*Secondary endpoint in pivotal trial of EUFLEXXA (n=157) vs
1. Rolling 12 month average of IQVIA claims data based on unique patients (August 2018-August 2019). 2. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 3. Nicholls M, Manjoo A, Shaw P, et al. A comparison between rheological properties of intra-articular hyaluronic acid preparations and reported human synovial fluid. Adv Ther. 2018;35(4):523-530. 4. Data on file. Ferring Pharmaceuticals Inc. 5. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.
EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].
EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.
EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
Do not inject intravascularly due to potential for systemic adverse events.
The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.
Please see FULL PRESCRIBING INFORMATION.